Pharmacotherapy: Biosimilar switching-"To set a form upon desired change"

Nature Reviews Rheumatology

Volumn 13, Issue 7, 2017, Pages 391-392

  Kay, Jonathan ^a   Winthrop, Kevin L ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; DRUG ANTIBODY; ETANERCEPT; ETANERCEPT SZZS; INFLIXIMAB; INFLIXIMAB DYYB; CT-P13; MONOCLONAL ANTIBODY;

CROHN DISEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MINIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; SPONDYLARTHRITIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; DOUBLE BLIND PROCEDURE;

ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; DOUBLE-BLIND METHOD; INFLIXIMAB;

EID: 85020958466     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2017.79     Document Type: Short Survey

References (10)

1. Jørgensen, K. K. et al. Switching from originator infliximab to biosimilar CT-P13 compared to maintained treatment with originator infliximab (NOR-SWITCH): a 52-week randomised double-blind non-inferiority trial. Lancet http://dx.doi.org/10.1016/ S0140-6736(17)30068-5 (2017).
2. Yoo, D. H. et al. A randomised, double-blind, parallelgroup study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann. Rheum. Dis. 72, 1613-1620 (2013).
3. Kay, J. & Isaacs, J. D. Clinical trials of biosimilars should become more similar. Ann. Rheum. Dis. 76, 4-6 (2017).
4. US Food & Drug Administration. Guidance for industry: considerations in demonstrating interchangeability with a reference product, draft guidance. FDA http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM537135 (2017).
5. Griffiths, C. E. et al. The EGALITY study: a confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis. Br. J. Dermatol. 176, 928-938 (2017).
6. Biologics Price Competition and Innovation Act of 2009, 119 United States Code, 7001-7003. https:// www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ UCM216146.pdf (2010).
7. Klein, A. V., Wang, J. & Bedford, P. Subsequent entry biologics (biosimilars) in Canada: approaches to interchangeability and the extrapolation of indications and uses. GaBI J. 3, 150-154 (2014).
8. Thimmaraju, P. K., Rakshambikai, R., Farista, R. & Juluru, K. Legislations on biosimilar interchangeability in the US and EU-developments far from visibility. GaBI Online http://www.gabionline.net/Sponsored-Articles/Legislations-on-biosimilar-interchangeabilityin-the-US-and-EU-developments-far-from-visibility (2015).
9. GaBI Online-Generics and Biosimilars Initiative. France to allow biosimilars substitution. GaBI Online http://www.gabionline.net/Policies-Legislation/Franceto-allow-biosimilars-substitution (2014).
10. Lunddahl, B. Pharmacovigilance on biologicals and biosimilars: a Danish perspective. GaBI J. 5, 123-124 (2016).